drugset / Trial / NCT02000882
STAR Cape+BKM120 MBC With Brain Met
NaSingle-groupOpen-labelTreatment
Summary
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer. Like capecitabine, BMK120 is also effective in crossing the blood brain barrier making it a preferred candidate for its evaluation in patients with metastatic breast cancer (MBC).
Timeline
- Start
- 2014-05-29
- Primary completion
- 2019-03-29
- Completion
- 2019-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 100 mg | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |